Literature DB >> 15525658

Orexin loss in Huntington's disease.

Asa Petersén1, Joana Gil, Marion L C Maat-Schieman, Maria Björkqvist, Heikki Tanila, Inês M Araújo, Ruben Smith, Natalija Popovic, Nils Wierup, Per Norlén, Jia-Yi Li, Raymund A C Roos, Frank Sundler, Hindrik Mulder, Patrik Brundin.   

Abstract

Huntington's disease (HD) is a devastating neurodegenerative disorder caused by an expanded CAG repeat in the gene encoding huntingtin, a protein of unknown function. Mutant huntingtin forms intracellular aggregates and is associated with neuronal death in select brain regions. The most studied mouse model (R6/2) of HD replicates many features of the disease, but has been reported to exhibit only very little neuronal death. We describe for the first time a dramatic atrophy and loss of orexin neurons in the lateral hypothalamus of R6/2 mice. Importantly, we also found a significant atrophy and loss of orexin neurons in Huntington patients. Like animal models and patients with impaired orexin function, the R6/2 mice were narcoleptic. Both the number of orexin neurons in the lateral hypothalamus and the levels of orexin in the cerebrospinal fluid were reduced by 72% in end-stage R6/2 mice compared with wild-type littermates, suggesting that orexin could be used as a biomarker reflecting neurodegeneration. Our results show that the loss of orexin is a novel and potentially very important pathology in HD.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15525658     DOI: 10.1093/hmg/ddi004

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  73 in total

1.  Protection by dietary restriction in the YAC128 mouse model of Huntington's disease: Relation to genes regulating histone acetylation and HTT.

Authors:  Cesar L Moreno; Michelle E Ehrlich; Charles V Mobbs
Journal:  Neurobiol Dis       Date:  2015-10-17       Impact factor: 5.996

2.  Dysfunctions in circadian behavior and physiology in mouse models of Huntington's disease.

Authors:  Takashi Kudo; Analyne Schroeder; Dawn H Loh; Dika Kuljis; Maria C Jordan; Kenneth P Roos; Christopher S Colwell
Journal:  Exp Neurol       Date:  2010-12-22       Impact factor: 5.330

3.  Hypocretin-1 (orexin A) levels are normal in Huntington's disease.

Authors:  Christian R Baumann; Martin Hersberger; Claudio L Bassetti
Journal:  J Neurol       Date:  2006-04-05       Impact factor: 4.849

4.  Microcirculation response to local cooling in patients with Huntington's disease.

Authors:  Ziva Melik; Jan Kobal; Ksenija Cankar; Martin Strucl
Journal:  J Neurol       Date:  2011-10-20       Impact factor: 4.849

5.  Functional roles for the striatal-enriched transcription factor, Bcl11b, in the control of striatal gene expression and transcriptional dysregulation in Huntington's disease.

Authors:  Paula A Desplats; James R Lambert; Elizabeth A Thomas
Journal:  Neurobiol Dis       Date:  2008-05-22       Impact factor: 5.996

Review 6.  Neurovascular glucocorticoid receptors and glucocorticoids: implications in health, neurological disorders and drug therapy.

Authors:  Sherice Williams; Chaitali Ghosh
Journal:  Drug Discov Today       Date:  2019-09-18       Impact factor: 7.851

7.  The wake-promoting effects of hypocretin-1 are attenuated in old rats.

Authors:  Stephen R Morairty; Jonathan Wisor; Kristy Silveira; William Sinko; Thomas S Kilduff
Journal:  Neurobiol Aging       Date:  2009-09-24       Impact factor: 4.673

8.  Responses to environmental enrichment differ with sex and genotype in a transgenic mouse model of Huntington's disease.

Authors:  Nigel I Wood; Valentina Carta; Stefan Milde; Elizabeth A Skillings; Catherine J McAllister; Y L Mabel Ang; Alasdair Duguid; Nadeev Wijesuriya; Samira Mohd Afzal; Joe X Fernandes; T W Leong; A Jennifer Morton; Jennifer Morton
Journal:  PLoS One       Date:  2010-02-12       Impact factor: 3.240

Review 9.  Genetic mouse models of Huntington's disease: focus on electrophysiological mechanisms.

Authors:  Carlos Cepeda; Damian M Cummings; Véronique M André; Sandra M Holley; Michael S Levine
Journal:  ASN Neuro       Date:  2010-04-07       Impact factor: 4.146

10.  Formation of polyglutamine inclusions in a wide range of non-CNS tissues in the HdhQ150 knock-in mouse model of Huntington's disease.

Authors:  Hilary Moffitt; Graham D McPhail; Ben Woodman; Carl Hobbs; Gillian P Bates
Journal:  PLoS One       Date:  2009-11-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.